Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06097728 · ClinicalTrials.gov registry record · Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
A Phase 3 study of Unresectable Pleural Mesothelioma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 825
- Enrollment target
- 20
- Study locations
NCT06097728: Recruiting Phase 3 study of Unresectable Pleural Mesothelioma, sponsored by AstraZeneca.
NCT06097728 is a Phase 3 study of Unresectable Pleural Mesothelioma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 825 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06097728, a Phase 3 study of Unresectable Pleural Mesothelioma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 825 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
Primary Outcome
OS is defined as the time from randomization until the date of death due to any cause.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Nivolumab
- DRUG Volrustomig
Study Locations (20)
Ohio
- Research Site - Cleveland
- Research Site - Cleveland
- Research Site - Cleveland
- Research Site - Columbus
- Research Site - Independence
California
- Research Site - Duarte
- Research Site - Santa Rosa
New York
- Research Site - Commack
- Research Site - Valhalla
Oregon
- Research Site - Portland
- Research Site - Portland
Arizona
- Research Site - Phoenix
Colorado
- Research Site - Aurora
Florida
- Research Site - Jacksonville
Georgia
- Research Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 825 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2028-11-16 |
| Phase | Phase 3 |
What NCT06097728 shows while recruiting
NCT06097728 is an interventional study that assigns participants to a tested intervention. The registered 825 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Unresectable Pleural Mesothelioma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06097728 names 20 study sites across 13 states, led by Ohio, California, New York.
Frequently Asked Questions
What is clinical trial NCT06097728 about?
NCT06097728 is a clinical study titled "MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma". This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
What is the current status of trial NCT06097728?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 825 participants. The study started on 2023-11-09. Estimated completion is 2028-11-16.
What conditions does trial NCT06097728 study?
This clinical trial studies the following conditions: Unresectable Pleural Mesothelioma.
What interventions are being tested in trial NCT06097728?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Nivolumab (DRUG), Volrustomig (DRUG).
Who is sponsoring clinical trial NCT06097728?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06097728 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06097728's enrollment target sits among peer trials
825 400th of 2000 higher than 1,600 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05630482 · 825 participants · NA
Randomized Trial of Healthy Family Foundations
- NCT07102641 · 825 participants · Phase 4
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
- NCT07318077 · 825 participants · NA
Radicle GI Health DBG: A Study Assessing the Impact of Health and Wellness Products on GI Health and Related Health Outcomes
- NCT06944509 · 824 participants · NA
RADIQAL Study (Radiation Dose and Image Quality Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI